Alliance Global raised the firm’s price target on Pelthos Therapeutics (PTHS) to $75 from $60 and keeps a Buy rating on the shares. The company’s Q3 report showed progress on the Zelsuvmi launch, the analyst tells investors in a research note. The firm says Zelsuvmi is the only use-at-home treatment for water warts.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTHS: